The RR6 model predicts survival in myelofibrosis based on clinical response after 6 months of ruxolitinib.
Maffioli M, Mora B, Ball S, Iurlo A, Elli EM, Finazzi MC, Polverelli N, Rumi E, Caramella M, Carraro MC, D'Adda M, Molteni A, Sissa C, Lunghi F, Vismara A, Ubezio M, Guidetti A, Caberlon S, Anghilieri M, Komrokji RS, Cattaneo D, Della Porta MG, Giorgino T, Bertù L, Brociner M, Kuykendall AT, Passamonti F. A Prognostic Model to Predict Survival After 6 Months of Ruxolitinib in Patients with Myelofibrosis. Blood Advances 2022. bloodadvances.2021006889. doi:10.1182/bloodadvances.2021006889
Risk stratum: -
Median overall survival*: months
Median o. survival* 95% CI: months
*counted from 6 months post ruxolitinib start.Total risk points:
Actuarial survival curves of the 3 risk groups of patients according to the Response to Ruxolitinib after 6 months (RR6) developed in ruxolitinib-treated myelofibrosis patients (training cohort).
Source: Maffioli et al., A Prognostic Model to Predict Survival After 6 Months of Ruxolitinib in Patients with Myelofibrosis. Blood Advances. doi:10.1182/bloodadvances.2021006889